2,432 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by J2 Capital Management Inc

J2 Capital Management Inc acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,432 shares of the biopharmaceutical company's stock, valued at approximately $273,000.

A number of other institutional investors also recently modified their holdings of GILD. Bridgewater Associates LP grew its position in Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after buying an additional 253,994 shares during the period. McAdam LLC increased its stake in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after buying an additional 3,627 shares during the period. Nissay Asset Management Corp Japan ADV raised its holdings in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares during the last quarter. Foster & Motley Inc. increased its position in Gilead Sciences by 80.4% during the 4th quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company's stock valued at $978,000 after purchasing an additional 4,718 shares during the period. Finally, Clear Creek Financial Management LLC purchased a new position in Gilead Sciences during the 4th quarter valued at $1,173,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Down 1.1%

Shares of NASDAQ GILD traded down $1.17 during midday trading on Monday, hitting $108.91. 9,986,911 shares of the stock traded hands, compared to its average volume of 7,723,769. The business has a 50 day moving average price of $105.49 and a two-hundred day moving average price of $100.90. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a market cap of $135.48 billion, a PE ratio of 294.35, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the firm posted ($1.32) EPS. The firm's quarterly revenue was down .3% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,929 shares of company stock worth $5,644,780. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Finally, Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.